Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000875320-26-000080 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-19 | 2026-02-17+ | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $484.87 | -2,195 | 8,388 | -21% | -$1.06M |
| 2026-02-19 | 2026-02-17 | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +1,809 | 10.5K | +21% | $0 | |
| 2026-02-19 | 2026-02-17 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $483.75 | -598 | 9,945 | -6% | -$289.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-18 | S | D | 638 | $473.68 | 7,750 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | A | A | 1,809 | $0.00 | 10,543 | D | — | — | (F1) Restricted stock unit award that vests in installments beginning on February 20, 2027. |
| 3 | Common | Common Stock | 2026-02-17 | F | D | 598 | $483.75 | 9,945 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-17 | S | D | 1,557 | $489.46 | 8,388 | D | — | — |